About Beta-1,3-galactosyltransferase 2
Beta-1,3-galactosyltransferase 2 (B3GALT2) is a protein
from Homo sapiens identified by UniProt accession
O43825, 422 residues long.
MolForge cross-references it against 0 known binders and
47 disease associations.
Target properties
| Protein name | Beta-1,3-galactosyltransferase 2 |
| UniProt accession | O43825 |
| Gene | B3GALT2 |
| Organism | Homo sapiens |
| Length | 422 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (47)
Diseases linked to this target (Open Targets).
- peripheral vascular disease · score 0.18
- PHF-tau measurement · score 0.16
- familial isolated hyperparathyroidism · score 0.12
- hyperparathyroidism · score 0.12
- Beta blocking agent use measurement · score 0.09
- lymphocyte count · score 0.08
- chronotype measurement · score 0.07
- lifestyle measurement · score 0.07
- breast carcinoma · score 0.06
- Diuretic use measurement · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O43825-F1 | alphafold | PREDICTED | 78.56 | — |
Amino-acid sequence (422 residues)
MLQWRRRHCC FAKMTWNAKR SLFRTHLIGV LSLVFLFAMF LFFNHHDWLP GRAGFKENPV TYTFRGFRST KSETNHSSLR NIWKETVPQT LRPQTATNSN NTDLSPQGVT GLENTLSANG SIYNEKGTGH PNSYHFKYII NEPEKCQEKS PFLILLIAAE PGQIEARRAI RQTWGNESLA PGIQITRIFL LGLSIKLNGY LQRAILEESR QYHDIIQQEY LDTYYNLTIK TLMGMNWVAT YCPHIPYVMK TDSDMFVNTE YLINKLLKPD LPPRHNYFTG YLMRGYAPNR NKDSKWYMPP DLYPSERYPV FCSGTGYVFS GDLAEKIFKV SLGIRRLHLE DVYVGICLAK LRIDPVPPPN EFVFNHWRVS YSSCKYSHLI TSHQFQPSEL IKYWNHLQQN KHNACANAAK EKAGRYRHRK LH
Explore Beta-1,3-galactosyltransferase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets